These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17129869)

  • 21. Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.
    Katano Y; Kumada T; Nakano I; Toyoda H; Ishigami M; Hayashi K; Honda T; Goto H
    Hepatogastroenterology; 2009; 56(90):485-91. PubMed ID: 19579626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
    Bani-Sadr F; Goderel I; Penalba C; Billaud E; Doll J; Welker Y; Cacoub P; Pol S; Perronne C; Carrat F;
    J Viral Hepat; 2007 Sep; 14(9):639-44. PubMed ID: 17697016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
    Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR
    Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
    Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
    J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
    Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
    J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
    Behler CM; Vittinghoff E; Lin F; Chung RT; Peters MG; Robbins GK; Volberding PA
    Clin Infect Dis; 2007 May; 44(10):1375-83. PubMed ID: 17443478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
    J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
    Glesby MJ; Bassett R; Alston-Smith B; Fichtenbaum C; Jacobson EL; Brass C; Owens S; Sulkowski M; Race EM; Sherman KE;
    J Infect Dis; 2005 Mar; 191(5):686-93. PubMed ID: 15688281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
    Raison CL; Borisov AS; Broadwell SD; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
    J Clin Psychiatry; 2005 Jan; 66(1):41-8. PubMed ID: 15669887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy.
    Drapeau CM; Remotti D; Noto P; Capone A; Boumis E; Petrosillo N
    J Chemother; 2008 Oct; 20(5):648-51. PubMed ID: 19028630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients.
    Préau M; Marcellin F; Spire B; Ravaux I; Dellamonica P; Blanc D; Carrieri MP
    J Clin Gastroenterol; 2008 Jan; 42(1):92-6. PubMed ID: 18097297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].
    Małyszczak K; Inglot M; Pawłowski T; Czarnecki M; Rymer W; Andrzej K
    Psychiatr Pol; 2006; 40(4):799-808. PubMed ID: 17068951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.
    Neri S; Pulvirenti D; Bertino G
    Clin Drug Investig; 2006; 26(11):655-62. PubMed ID: 17163300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.
    Rasimas J; Katsounas A; Raza H; Murphy AA; Yang J; Lempicki RA; Osinusi A; Masur H; Polis M; Kottilil S; Rosenstein D
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):273-81. PubMed ID: 22728749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
    Schaefer M; Mauss S
    Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients.
    Quereda C; Corral I; Moreno A; Pérez-Elías MJ; Casado JL; Dronda F; Rodríguez-Sagrado MA; Hernández B; Moreno S
    J Acquir Immune Defic Syndr; 2008 Sep; 49(1):61-3. PubMed ID: 18667933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
    Vignau J; Costisella O; Canva V; Imbenotte M; Duhamel A; Lhermitte M
    Encephale; 2009 Oct; 35(5):477-83. PubMed ID: 19853722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.